A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

NCT02808793 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Systemic Mastocytosis

Interventions

DRUG: AK002

Sponsor

Allakos Inc.